The aim of this study was to identify novel substrates of the FANCcore complex, which inactivation leads to the genetic disorder Fanconi anemia (FA), which associates bone marrow failure, developmental abnormalities and predisposition to cancer. Eight FANC proteins participate in the nuclear FANCcore complex, an E3 ubiquitin-ligase that monoubiquitinates FANCD2 and FANCI in response to replicative stress. Here, we used mass spectrometry to compare proteins from FANCcore complex deficient FA-A and FA-C cells to their ectopically corrected counterparts challenged with hydroxyurea, an inducer of FANCD2 monoubiquitination. Our work has uncovered a pathway involving FANCA in neddylation and cell motility.
Introduction
Protein activity, stability and/or subcellular localization are precisely regulated through several post-translational modifications (PTMs) (Cai et al., 2012; Han and Martinage, 1992) . Among several known PTMs, ubiquitinylation is based on the addition of ubiquitin chains to targets proteins via a three steps process. The ubiquitin protein is a mature 76 aa polypeptide that weighs 8.5 kDa. It is first attached to the E1 ubiquitin-activating enzyme. It is then transferred to a ubiquitin-conjugating enzyme (Ubc or E2), which will then interact with an ubiquitin ligase (E3) that will complete the ubiquitin transfer to a specific lysine (K) on the target protein (Komander and Rape, 2012) .
Ubiquitination marks protein for proteasomal degradation or to regulate their function or subcellular localization (Chen and Sun, 2009 ). The hypothesis that ubiquitination plays a regulatory role is supported by the identification of a family of deubiquitinating enzymes (DUBs) that are involved in the rapid and specific deubiquitination of Ub-modified proteins (Clague et al., 2012) . Furthermore, other ubiquitin-like proteins (UBLs), such as Small Ubiquitin-like MOdifier (SUMO), Neural precursor cell Expressed Developmentally Downregulated 8 (NEDD8) and Interferon Stimulated Gene 15 product (ISG15), have been identified; these proteins undergo processes analogous to the ubiquitinylation pathway and play roles similar to that of ubiquitin. UBLs often target the same proteins at the same sites as ubiquitin.. Among the several identified UBLs, NEDD8 is the closest relative to ubiquitin and may regulate the ubiquitinylation process (Xirodimas, 2008) . For example, NEDD8 targets the Epidermal Growth Factor Receptor (EGFR) and stimulates its ubiquitinylation, which is required for receptor internalization and degradation or recycling (Oved et al., 2006) . In addition, NEDD8 also targets the Cullin family of proteins, in which neddylation induces the conformational changes that are necessary for their activity (Pan et al., 2004) . While few E1, E2, E3 and deconjugating NEDD8 enzymes have been identified to date, the dynamic and reversible circuitry of the ubiquitinylation and deubiquitination processes involves two E1s and approximately 40 E2s, 600 E3s and 90 DUBs. The E3 family comprises two groups. The members of one group contain the Homologous to the E6-AP Carboxyl Terminus (HECT) domain, and the members of the other group contain a Real Interesting New Gene (RING) domain. The RING-E3 subfamily consists of E3 proteins that directly link both the E2 and the target protein, and E3s that link only the E2 while the target protein interacts with another component of a multi-protein complex that includes the E3 (Acconcia et al., 2009; Chen and Sun, 2009; Deshaies and Joazeiro, 2009 ).
The FANCcore complex is an E3 multiprotein complex that hosts the E3 RING ligase FANCL, which, in collaboration with the E2 UBE2T, catalyzes the transfer of a mono-ubiquitin to the downstream targets FANCD2 and FANCI (Alpi et al., 2007; Alpi et al., 2008; Machida et al., 2006 (Bogliolo et al., 2013; Kashiyama et al., 2013; Kim and D'Andrea, 2012) . A biallelic mutation in any of the 16 identified FANC genes causes the rare DNA damage response (DDR) syndrome Fanconi anemia (FA). The symptoms of FA include bone marrow failure, genetic instability, a predisposition for acute myeloid leukemia and head and neck cancers (Soulier, 2011) , altered free radical generation/detoxification (Pagano et al., 2012) and abnormalities in cytokine production/responses (Briot et al., 2008; Pang et al., 2001; Rosselli et al., 1992) . This clinical and cellular heterogeneity could actually result from a general disturbance of the cell and tissue metabolism as a consequence of a DDR defect, but it may also be caused by alternative activities of a single FANC protein or the existence of other currently unidentified targets of the FANCcore complex.
To further elucidate the cellular and clinical consequences of FANC pathway inactivation, in this study we aimed to identify and characterize novel targets of the FANCcore complex's E3 ubiquitin-ligase activity. FANCD2 and FANCI appear to be the only true direct targets of the nuclear FANCcore complex. Surprisingly, the majority of the other proteins that was identified as potential FANCA or FANCC targets localize to the cell membrane. Finally, we demonstrate that the chemokine receptor CXCR5 is neddylated in a FANCA-dependent manner through a currently unknown mechanism and that CXCR5 neddylation is involved in the targeting of this receptor to the cell membrane and in optimizing cell migration/motility.
Results

Looking for FANCcore complex post-translational modified proteins.
To identify novel substrates of the ubiquitin ligase activity of the FANCcore complex and involved in its heterogeneous phenotype, we used a recently developed approach based on the immunoaffinity enrichment of peptides that are modified by ubiquitin or ubiquitin-like (NEDD8 and ISG-15) chains using antibodies that are specifically directed against the K-GG moiety that remains on the modified lysine residues after the trypsin digestion of a cellular extract ( Figure 1A) . We compared the proteins extracted from exponentially growing HSC-72 (FANCA-deficient) and HSC-536 (FANCC-deficient) FANCcore complex-deficient lymphoblasts with the proteins from their ectopically corrected counterparts HSC-72corr and HSC-536corr, respectively, after treatment with the replication inhibitor hydroxyurea, which is a strong inducer of FANCcore complex activity and Tables S1 and S2). We expected to identify other proteins (i.e., the corresponding peptides) at high concentration levels in the FA-corrected cells and with fold changes between the FA-corrected and FA cells that were similar to FANCD2 and FANCI in both the FANCA and FANCC analysis. Surprisingly, we did not identify other proteins with a FANCD2 and FANCI similar ratio, which suggests that FANCD2 and FANCI may be the only targets of the FANCcore complex.
The peptides identified comparing the FANCC-deficient to the FANCC-corrected cell revealed 415 individual proteins that were modified by ubiquitin or a ubiquitin-like moiety (Supplemental Table S1 ). In addition to FANCD2 and FANCI, we found relatively few proteins that had a significant Z-score and/or a robust (>2.5) FANCC-proficient/FANCC-deficient cell ratio (Supplemental Table S1 and Figure 1B ). Only one polypeptide belonging to the uncharacterized transmembrane glycan-binding receptor on dividing B cells C-type lectin domain family 17, member A isoform 1 (CLEC17A or prolectin) protein (Koh et al., 2011) exhibited a fold change that was similar to the values obtained for FANCD2 and FANCI.
When we compared the FANCA-deficient cells with the FANCA-corrected cells, we identified 471 unique proteins, including FANCD2 and FANCI (Supplemental Table S2 and Figure 1C ). Of the proteins identified in our FANCC analysis, 287 were also identified in the FANCA analysis ( Figure   1D -E and Supplemental Table S3 ). Of the 76 proteins identified in the FANCA analysis that had a high FANCcore complex-proficient/deficient ratio (>2.5) and/or a significant Z-score, only three were also identified in the FANCC analysis ( Figure 1C and Supplemental Table S3 ). These three proteins were FANCD2, FANCI and the nuclear-encoded NDUFA8 subunit of NADH:ubiquinone oxidoreductase, which is part of the first mitochondrial respiratory chain complex (Triepels et al., 1998) . Only FANCD2 and FANCI, however, had highly significant FANCcorrected/FANCdeficient ratio, which was consistent with their already known direct ubiquitinylation by the FANCcore complex.
Surprisingly, for both the FANCA and FANCC analyses, the majority of the identified proteins appears to be localized outside of the nucleus and specifically appears to be localized to the membranes ( Figures 1B, 1C and Supplemental Figure 1 ). Because we failed to identify novel targets of the FANCcore complex, we next examined the sensitivity of our approach. Among the identified post-translationally modified proteins, we identified the well-known replication stress-induced monoubiquitinated peptide of PCNA and a peptide from the DNA replication-licensing factor MCM7. There was no significant difference in the level of these peptides between the FA and FAcorrected cells. The monoubiquitination of FANCD2 and PCNA was easily detected by immunoblot (Supplemental Figure 2A and B), but we needed to perform an immunoprecipitation with anti-MCM7 or anti-ubiquitin (FK2) antibodies to enrich and detect the Ub-modified MCM7 form prior to Western blot analysis. Using this technique, we demonstrate that MCM7 is monoubiquitinated (Supplemental Figure 2C ). According to the Mass Spectrometry (MS) results, however, there was no significant difference in the MCM7 or PCNA monoubiquitination levels that correlated with the proficiency of the FANC pathway.
Because of these findings, we are confident that the approach used in this study was sufficiently sensitive and specific to achieve our goal. Therefore, the proteomics results from this study suggest that the FANCcore complex is only involved in FANCD2 and FANCI monoubiquitination and that some of its components may act independent of each other in other pathways and cellular localizations.
CXCR5 is a neddylated protein, and FANCA is involved in its neddylation.
Among the proteins identified in the FANCA analysis, CXCR5, B2M and SLAMF7 may be potential targets of a FANCA-regulated activity through currently unknown mechanisms. To confirm a role for FANCA in these differences observed in our study, we continued our characterization of the observed PTM of the transmembrane chemokine receptor CXCR5, which plays a role in B cell behavior, cancer progression, cancer invasion and auto-immune and pro-inflammatory diseases (Muller et al., 2003; Pevzner et al., 1999) . To determine whether the difference observed in the MS analysis was the result of a modified expression of CXCR5 in the FA-derived cells or of a FANCAinduced CXCR5 overexpression, we used Western blot to determine the CXCR5 expression level at steady state and following HU treatment. The FA cells and their corrected counterparts have similar CXCR5 expression levels excluding bias in the MS data ( Figure 2A) . Next, the proteins extracted from the FANCA-and FANCC-deficient cells and their corrected counterparts were immunoprecipitated using the anti-Ubiquitin antibody FK2, and an immunoblot analysis was conducted using an anti-CXCR5 antibody and an anti-PCNA antibody as a positive control for the IP.
Unexpectedly, we failed to identify a CXCR5 ubiquitinylated form (Supplemental Figure 3A) . The K-GG moiety that is created by the trypsin digestion of the protein extract before the MS analysis and that is recognized by the specific antibody used to enrich ubiquitin-modified peptides is also a signature of NEDD8 and ISG15 PTMs. Consequently, we immunoprecipitated the protein extract from FANC-proficient EBV-transformed HSC93 lymphoblasts using either an anti-NEDD8 or an anti-CXCR5 antibody and conducted an immunoblot analysis using an anti-CXCR5 antibody, which revealed the presence of a specific albeit minor CXCR5 neddylated form ( Figure 2B ). To confirm the observed CXCR5 neddylation, we followed two complementary approaches. First, we demonstrated that the presumed neddylated-CXCR5 band is no longer revealed in cells treated with the NEDD8 specific inhibitor ML4924 (Wei et al., 2012) (Figure 2C ), which is able to eliminate the known neddylated form of Cul4A (Supplemental Figure 2B ) without modification of the CXCR5 level (Supplemental Figure 2A) . Secondly, we used the proximity ligation assay (PLA) technology on fixed cell using anti-NEDD8 and anti-CXCR5 antibodies ( Figure 2D ). Exposure to the NEDD8 inhibitor significantly reduced the number of CXCR5-NEDD8 spots per cell ( Figure 2E ). Finally, we performed a NEDD8 immunoprecipitation using cellular extracts from the FA and FA-corrected cells ( Figure 2F ). The immunoblot demonstrates that the expression level of the CXCR5 neddylated form is elevated in the FANCA-corrected but not the FANCC-corrected lymphoblasts when compared with the respective FA cells ( Figure 2G ).
In conclusion, using a combination of different approaches, we identified CXCR5 as a new member of the yet restrained group of neddylated proteins, validating the results from our proteomics analysis, and we disclosed that FANCA, but not the FANCcore complex, plays a role in the process of CXCR5 neddylation.
Neddylation is responsible for targeting CXCR5 to the cell membrane and cell motility.
Since neddylation has been involved in EGFR trafficking (Oved et al., 2006) , we wanted determine if this was also the case for the CXCR5 neddylation here identified. Therefore, by FACS analysis, we quantified the amount of CXCR5 localized to the plasma membrane in several cell lines.
Consistently with the hypothesis that the addition of NEDD8 to CXCR5 is involved in its targeting to the cell membrane, the FANCA-corrected cells showed the highest level of membrane-associated receptor among the analyzed EBV-transformed lymphoblastoid cell lines ( Figures 3A and 3B ).
To confirm and expand on our previous results showing that CXCR5 is neddylated in a FANCA-dependent manner and that neddylation is required for the optimal targeting of CXCR5 to the membrane, we used different approaches. First, we treated the FANCA-corrected cells with the NEDD8 inhibitor MLN4924. As expected, the MLN4924 treatment reduced the level of membraneassociated CXCR5 in the FANCA-corrected cells in a dose-dependent and highly significant manner ( Figure 3C ). This finding supports the hypothesis that neddylation is important for the optimal targeting of CXCR5 to the cell surface. Next, we transfected U2OS cells with either a full-length, wild-type form of CXCR5 or a mutant CXCR5-K339R form that cannot be neddylated (Supplemental figure 3C) . Compared with the untransfected cells, there was an increase in the protein level on the membranes of the cells overexpressing WT-CXCR5. Furthermore, the CXCR5-K339R mutant, which was expressed at the same level as the WT-CXCR5, was less targeted to the membrane ( Figures 3D and 3E ).
Finally, it has been reported that the overexpression of the oncogenic transcription factor MiTF in the metastatic melanoma cell line MEL501, which was isolated from a lymphatic node, is associated with FANCA mRNA overexpression (Strub et al., 2011) . Taking Consequently, using several different approaches and cell models, we demonstrated that CXCR5 is post-translationally modified by the addition of NEDD8 through a mechanism regulated by FANCA and that this PTM is important for targeting this protein to the plasma membrane.
CXCR5 is involved in B cell motility and migration to the germinal centers in the spleen and Peyer's patches in response to its ligand CXCL13 (Förster et al., 1996) . To determine whether CXCR5 neddylation plays a role in cell mobility, we used a wound-healing assay to compare the motility of U2OS cells expressing either a wild-type CXCR5 protein or the CXCR5-K339R mutant that cannot be neddylated. Wound closure after inflicting a scratch wound to the U2OS monolayer culture was significantly reduced when the K339R CXCR5 mutant was overexpressed ( Figure 4A and 4B). This finding indicates that a motility defect is associated with a defect in CXCR5 neddylation
Discussion
To further elucidate the molecular pathways that are altered in FA and involved in its We demonstrated that (a) the chemokine receptor CXCR5 is a neddylated protein, (b) FANCA modulates CXCR5 neddylation through a currently unknown mechanism, (c) CXCR5 neddylation is involved in the targeting of the receptor to the cell membrane and (d) cell migration/motility is stimulate/optimized by CXCR5 neddylation ( Figure 4C ).
Further in-depth studies are needed to elucidate the precise role that neddylation plays in CXCR5 function, identify the enzymes that are directly involved in this process, determine how FANCA regulates CXCR5 neddylation and determine the role that CXCR5 plays in the FA cellular and clinical phenotypes. CXCR5-dependent signaling is involved in B cell terminal differentiation, immune responses, cancer progression, cancer invasion and pro-inflammatory diseases (Hardtke et al., 2005; Yu et al., 2012) . The existence of a mechanism that regulates the precise interplay between the FANC and neddylation pathways is supported not only by the findings from our present study but also by several published observations. NEDD8 target proteins are involved in chromatin remodeling and DNA repair and replication (Jones et al., 2002; Xirodimas, 2008) , in which the FANC pathway is also involved. Neddylation inhibition increases CHK1 stability and G2/M checkpoint (Yang et al., 2012) , which are two major cellular features associated with FA loss-of-function (Guervilly et al., 2011) . Additionally, neddylation negatively regulates the transcriptional activity of NF-kB and p53 (Abida et al., 2007; Gao et al., 2006; Xirodimas et al., 2004) , and the activity of these transcription factors is increased in FANC pathway-deficient cells. These findings further support the hypothesis that there is a potential neddylation defect in FA. Finally, NEDD8 and neddylation are involved in FANCD2 monoubiquitination and relocalization to chromatin foci (Kee et al., 2012) . Consequently, inhibition of the neddylation pathway results in a FA-like cellular phenotype.
Barroca et al. recently reported that a CXCR4-CXCL12 signaling defect results in changes
in the migration of FANCG-KO MEF and LSK cells (Barroca et al., 2012) , which supports the hypothesis that defects in the signaling pathway occur downstream of the C-X-C receptors and that these defects could contribute to the bone marrow failure and developmental abnormalities associated with FA syndrome. Previous studies have shown that there is important functional crosstalk between CXCR4 and CXCR5 in B cell and secondary lymphoid organ behavior (Schmidt et al., 2013) . Since FANCA and FANCG should form a cytoplasmic subcomplex (Medhurst et al., 2006) , and Barroca et al. failed to identify the cause of the CXCL12-CXCR4 signaling defects in the FANCG-KO cells (Barroca et al., 2012) , it is tempting to speculate that the cause of this defect is dependent on the changes in CXCR5 neddylation that we observed in this study.
In conclusion, our findings revealed a connection between FANC proteins, the neddylation pathway and membrane receptor signaling and allude to new potential mechanisms that provide a more integrated view of the FA syndrome. Moreover, our findings may serve as a starting point to discover how crosstalk between the signaling pathways involved in ubiquitination, neddylation and other induced PTMs regulate cell physiology and developmental processes.
Materials and Methods
Cell lines, culture conditions and treatments.
We used EBV-immortalized lymphoblastoid cell lines HSC-72 (FA-A) and HSC-536 (FA-C), their respective corrected counterparts HSC-72corr and HSC-536corr, HSC-93 (WT), EGF088 (FA-A) and HSC-99 (FA-A) as well as U2OS and 501Mel cell lines. Cells were grown in RPMI or DMEM medium supplemented with fetal bovine serum, 1 mM sodium pyruvate, 100 U/mL penicillin, 100 ug/mL streptomycin and 0.5 g/ml puromycin (all from Invitrogen) at 37°C and 5% CO 2 (all from Invitrogen) at 37°C and 5% CO2.
Cells were collected by centrifugation 8 h after exposure to 5 mM hydroxyurea (HU), flash frozen and stored at -80°C. Protein extraction, mass spectrometry and proteomic analysis were performed by the Cell Signaling Ubiquitin core facility.
Treatments with the NEDD8 inhibitor (MLN4924, Millennium Pharmaceutical), prepared as a 10 mM stock solution in DMSO, were performed at the doses and times indicated.
Proteomics analysis.
For the K-GG peptide immunoprecipitation and LC-MS/MS analysis, cell pellets were sent on dry ice to Cell Signaling Technology for UbiScan analysis using the ubiquitin branch antibody. A brief description of the protocole is given in spupplemental informations. The in silico protein interactions were determined using the StringDatabase with a confidence score > 0.7.
Transfection.
The siRNA control (5′-CGUCGACGGAAUACUUCGA-3′) was purchased from Eurogentec. siRNA against MiTF (SMARTpool), FANCC (SMARTpool) and FANCA (SMARTpool) were purchased from Dharmacon. siRNA (20 nM) was transfected into cells using INTERFERIN (Polyplus), and the experiments were conducted 48 h after. For the overexpression experiment, 2 µg of the FANCA-flag expressing vector (a gift from A.
Constantinou), CXCR5 WT (from DNAsu) and K339R were transfected using Turbofect (Fermentas) according to the manufacturer's protocol, and the experiments were conducted 24 h later.
Antibodies.
We used the following antibodies: rabbit anti-MCM7 ( The isotype antibodies mouse IgG1,and IgG2a,b and rabbit IgG were obtained from Dako.
Western blot analysis
The collected cells were disrupted in lysis buffer (50 mM Tris pH 7.9, 40 mM NaCl, 1 mM MgCl2, 0.1% SDS and 1% Benzonase (Novus) supplemented with protease and phosphatase inhibitors (Roche)). After 20 min incubation at RT, the protein concentration was determined using the Bradford assay (BioRad), and samples were combined with 4X Laemmli buffer containing β-mercaptoethanol and denatured by boiling. The proteins (25 µg) were separated by SDS-PAGE.
All Western blot quantifications were performed using densitometry measures and the ImageJ software (http://rsb.info.nih.gov/ij/).
Protein Immunoprecipitation.
The proteins were extracted using NETN buffer (150 mM NaCl, 50 mM Tris pH 8.0, NP-40 0.5-1% and EDTA 1 mM) and sonicated to fragment the DNA. The extracts were precleared using a non-specific antibody for 1 h at 4°C. The cleared extracts were added to magnetic protein G beads (Millipore) coated with a specific antibody and incubated overnight at 4°C. Control immunoprecipitations were conducted using a non-specific isotype antibody under the same conditions. After five washes in NETN buffer, the immune complexes were eluted by boiling for 5 minutes in 35 µL 2X Laemmli buffer and denaturated by boiling for another 5 minutes in the presence of 1 µl 1 M β-mercaptoethanol.
FACS analysis.
Cells were harvested and washed once in cold PBS before centrifugation at 1200 rpm for 5 minutes. The pellets were resuspended in PBS containing 3% BSA with an Alexa 488-coupled CXCR5 antibody diluted 1:100 and incubated for 1 h at room temperature under dark conditions.
After two washes with cold PBS, the cells were incubated in PBS containing 3% BSA and analyzed using a C6 cytometer with CFlow software (Accuri).
Proximity Ligation Assay.
Briefly, cells were fixed with 4% paraformaldehyde (Sigma) for 10 minutes at RT and then permeabilized in PBS containing Tween-20 (0.05%) and Triton (0.5%) (both from Sigma) for 5 minutes. After being blocked in PBS-BSA 2%, the cells were incubated in primary antibody diluted in PBS-BSA 2% for 2 h and then incubated in PLA probe for 30 minutes at 37°C. Next, ligation and amplification were performed following the manufacturer's protocol. Finally, the slides were mounted in fluorescent medium (DAKO) supplemented with DAPI (Sigma) and analyzed at a magnification of 63x using fluorescence microscopy (Zeiss Axio Observer Z1). Images were captured using an Orca-ER Camera (Hammamatsu).
Wound-healing Assay.
U2OS were seeded at a density of 200,000 cells in six-well plates and transfected with CXCR5
plasmid for 48 h. The cells were incubated in a serum-free medium overnight. Next, the cells were scratched using a fine tip, and pictures were taken at different time points (0, 5, and 8 hours) with a Zeiss inverted microscope and an AxioCam MRm camera. The images were analyzed using AxioVision software.
Statistical analysis.
Significance was determined by using a 2 tails t-test. P-values less than 0.05 were considered as significant. G. Relative quantification of the immunoprecipitated band from three independent experiments is also shown. Significance was calculated using the t-test. F and G. FACS analysis results for the CXCR5 membrane expression level in 501mel cells (F) and after treatment with Nedd8 inhibitor (G).
H. FACS analysis results for the membrane-associated CXCR5 expression level in 501mel cells after the MiTF or FANCA expression levels were reduced. 501mel cells were transfected with the indicated siRNA for 48 h and stained with the CXCR5 antibody as described elsewhere. FANCA  ?  CXCR5-NEDD8  membrane associated CXCR5  cell mobility C
